With passion for rheumatology! Recently, three new fluorescence patterns were added to the classification tree of the International Consensus on Antinuclear Antibody Patterns (ICAP)1. ICAP is an initiative of international scientists with the goal of evaluating the large number of ANA patterns in a standardised way. ANA (antinuclear antibodies) are biomarkers for different autoimmune diseases, […]
Vesicular glutamate transporter 2 (VGLUT2) has been identified as a novel target antigen of autoantibodies in patients with neurological disorders, frequently accompanied by comorbidities with cardiovascular and inflammatory involvement. The discovery was made in a collaborative study between Euroimmun and different laboratories and clinics in Germany, which was published recently in the journal Brain, Behavior,
On 15th April 2025, the European Commission authorised lecanemab (monoclonal anti-amyloid (beta) antibody; trade name: Leqembi from Eisai and Biogen) in the European Union to treat early Alzheimer’s disease. A decision was long awaited after the positive opinion on the marketing authorisation of the medicine by the European Medicines Agency (EMA) in November 2024. The
The EUROIMMUN Anti-Acetylcholine Receptor ELISA shows a high overall concordance with traditional radioimmunoassay (RIA) in patients with myasthenia gravis (MG), while offering advantages such as avoidance of radioisotope waste. This was the conclusion of a study on patients in Japan, which was performed as part of a collaboration between EUROIMMUN and scientists at the Neurology
A multiparameter EUROLINE blot for detection of myositis-related autoantibodies showed a high agreement with muscle biopsy results in patients with idiopathic inflammatory myopathies (IIM), suggesting it can be used as a first-line diagnostic tool in the diagnostic workflow. The recently published study was performed as part of a collaboration between scientists from EUROIMMUN Brazil and
